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Objective: Previous research suggests a positive association between pain, depression
and sleep. In this study, we investigate how sleep correlates with varying levels of pain
and depression in nursing home (NH) patients with dementia.
Materials and methods: Cross-sectional study (n = 141) with sleep-related data,
derived from two multicenter studies conducted in Norway. We included NH patients
with dementia according to the Mini-Mental State Examination (MMSE ≤ 20) from the
COSMOS trial (n = 46) and the DEP.PAIN.DEM trial (n = 95) whose sleep was objectively
measured with actigraphy. In the COSMOS trial, NH patients were included if they were
≥65 years of age and with life expectancy >6 months. In the DEP.PAIN.DEM trial,
patients were included if they were ≥60 years and if they had depression according
to the Cornell Scale for Depression in Dementia (CSDD ≥ 8). In both studies, pain was
assessed with the Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale
(MOBID-2), and depression with CSDD. Sleep parameters were total sleep time (TST),
sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset (WASO), early
morning awakening (EMA), daytime total sleep time (DTS) and time in bed (TiB). We
registered use of sedatives, analgesics, opioids and antidepressants from patient health
records and adjusted for these medications in the analyses.
Results: Mean age was 86.2 years and 76.3% were female. Hierarchical regressions
showed that pain was associated with higher TST and SE (p < 0.05), less WASO
(p < 0.01) and more DTS (p < 0.01). More severe dementia was associated with more
WASO (p < 0.05) and TiB (p < 0.01). More severe depression was associated with less
TST (p < 0.05), less DTS (p < 0.01) and less TiB (p < 0.01). Use of sedative medications
was associated with less TiB (p < 0.05).
Conclusion: When sleep was measured with actigraphy, NH patients with dementia
and pain slept more than patients without pain, in terms of higher total sleep time.
Furthermore, their sleep efficiency was higher, indicating that the patients had more
Frontiers in Psychology | www.frontiersin.org 1 April 2021 | Volume 12 | Article 633959
fpsyg-12-633959 April 19, 2021 Time: 12:58 # 2
Blytt et al. Sleep, Pain and Depression
sleep within the time they spent in bed. Patients with more severe dementia spent
more time awake during the time spent in bed. Furthermore, people with more
severe depression slept less at daytime and had less total sleep time Controlling for
concomitant medication use did not affect the obtained results.
Keywords: sleep, pain, depression, nursing home patients, actigraphy, dementia
INTRODUCTION
Approximately 50 million people are living with dementia
worldwide, and every year 10 million new cases are registered
(World Health Organization [WHO], 2019). Sleep disturbances,
like difficulties in initiating sleep, frequent awakenings, excessive
daytime sleepiness and nighttime wandering are often seen in
people with dementia (McCleery et al., 2016; Webster et al.,
2020a). However, to estimate the prevalence of sleep disturbances
in people with dementia is difficult due to differences in
assessment methods and because of the patients’ reduced
communicative ability (Blytt et al., 2017).
A recent systematic review and meta-analysis conducted by
Webster et al. (2020b) found a 20% pooled prevalence of clinically
significant sleep disturbances in people with dementia and a 70%
prevalence of sleep disturbances as measured with actigraphy.
Furthermore, Webster et al. (2020a) found that sleep disturbances
negatively affect physical and psychological well-being in people
with dementia. In the NH setting, sleep disturbances also caused
disruption for other patients and increased stress among staff
(Webster et al., 2020a). Previously conducted studies have found
that sleep disturbances in dementia are associated with reduced
quality of life and impaired daytime functioning (Kyle et al.,
2010), increased family burden and earlier nursing home (NH)
admission, thereby increasing the social and economic costs for
society (McCrae et al., 2016; Livingston et al., 2017).
Pain is a subjective experience that is difficult to assess
for people with dementia, due to reduced capacity to give
valid self-report (Blytt et al., 2017). When assessed by
proxy-rater measurements, moderate to severe pain is found
in approximately 40–60% of NH patients with dementia
(Achterberg et al., 2010; Hemmingsson et al., 2018; Wagatsuma
et al., 2020). Reduced quality of life, increased agitation and
anxiety are all associated with pain in NH patients (Ballard et al.,
2009). In addition, approximately 50% of people with dementia
experience symptoms of depression – a condition that may
reduce their quality of life and accelerate the decline in cognition
and daily functioning (Enache et al., 2011).
Previous research has found a reciprocal relationship between
pain and depression in people without dementia (Bair et al.,
2003; Goldenberg, 2010; Kroenke et al., 2011). This relationship
is known as the “pain-depression dyad,” indicating that the
conditions often coexist, respond to similar treatment and share
common signal pathways (Chopra and Arora, 2014). In NH
patients, Erdal et al. (2017) found that reduced pain intensity was
associated with subsequent reduction of depressive symptoms,
regardless of analgesic or antidepressant use. These associations
were found in patients with mild, moderate and severe cognitive
impairment. However, results on the primary outcome measures
in an analgesic intervention trial did not support a direct causal
relationship between pain and increased depression in NH
patients with dementia (Erdal et al., 2018).
There is also considerable evidence for a reciprocal
relationship between pain and sleep in people without dementia.
Previous research suggests that poor sleep may affect the
perception of pain (Sivertsen et al., 2015), but also that pain
in itself can be a possible cause of poor sleep (Sivertsen et al.,
2015; Flo et al., 2017). There is some evidence suggesting that
depression may be a central underlying mechanism in the
relationship between pain and sleep in people without cognitive
impairment (Ravyts et al., 2018). Furthermore, pain may lead to
depression, which in turn may affect the patient’s sleep (Nicassio
et al., 2012; Flo et al., 2017). By extension people with dementia
and depression may be lying in bed, experiencing trouble falling
asleep or maintaining sleep because they are in pain (Blytt,
2019). However, there is still a lack of evidence regarding this
relationship in people with dementia (Flo et al., 2017).
To our knowledge, there are no previous studies investigating
how sleep is associated with pain and depression in NH patients
with dementia. Given the frequency and clinical implications of
sleep disturbances for the patients, co-residents and staff, new
knowledge regarding the relationship between pain, depression
and sleep in this patient group is valuable. Consequently,
we aimed to investigate the association between sleep, pain,
depression and dementia in NH patients. We hypothesized that
a) more pain was associated with poorer sleep; b) more severe
dementia was associated with poorer sleep; and c) more severe
depression was associated with poorer sleep. Because medical
treatment for pain, depression and sleep disorders may also
impact sleep parameters, analyses were adjusted for the use of
analgesic, antidepressant and sedative-hypnotic drugs.
MATERIALS AND METHODS
Participants and Protocol
The study was based on sleep-related data derived from two
independent multicenter studies conducted in Norway: the
COSMOS trial (n = 46) and the DEP.PAIN.DEM trial (n = 95).
The COSMOS (Communication, Systematic pain assessment and
treatment, Medication review, Organization of activities, and
Safety) trial is a multicenter cluster-randomized controlled trial
over 4 months with follow-up at month 9. The study was
conducted from January 2014 to December 2015. It aimed
to improve the quality of life among NH patients through a
multicomponent intervention (Husebo et al., 2015). A total of
765 patients were invited to participate in the COSMOS study,
and 545 participants from 67 NH units were included (Husebø
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et al., 2019). The COSMOS trial used the following inclusion
and exclusion criteria: NH patients ≥65 years of age and life
expectancy >6 months.
The DEP.PAIN.DEM trial is a multicenter, placebo-controlled
randomized clinical trial over 13 weeks. The study was conducted
in Norway from August 2014 to September 2016. The main
aim of the DEP.PAIN.DEM trial was to investigate the efficacy
of pain treatment on depression in people with dementia
and depression. Patients were included if they were long-
term NH patients ≥60 years with >4 week stay at inclusion,
dementia according to the Mini-Mental State Examination
(MMSE score ≤ 20) and depression according to the Cornell
Scale for Depression in Dementia (CSDD score ≥ 8). The sleep
subproject of DEP.PAIN.DEM included 106 patients from 47
NHs (Blytt et al., 2018a).
Patients with Parkinson disorder or any form of paralysis
in the arms or upper body were excluded from actigraphy
registrations. In the present study, we included patients who
had valid actigraphy measurements and dementia according to
MMSE (≤20) from both the DEP.PAIN.DEM and the COSMOS
trials, which implies that we used data collected at baseline (week
0) before any intervention was conducted.
In total, 141 patients from the COSMOS (n = 46) and
the DEP.PAIN.DEM (n = 95) trials had valid actigraphy
measurements and dementia according to MMSE and were
included in the present study. Some of the respondents did not
have complete datasets for all variables (see Table 1 for the
number of observations for the different variables). Mean age was
86.2 years and 76.3% were female.
In the data collection process, the patient’s medical decision-
making capacity was discussed with the patient’s primary nurse at
the NH. Efforts were made to adjust the information for patients
who had reduced capacity to give consent (MMSE score from
16 to 19). In addition, the researchers telephoned all the eligible
patients’ legal guardians. If the legal guardians gave presumed
consent on behalf of the patient, they received written and oral
information together with a consent form that they signed and
mailed back. The DEP.PAIN.DEM study was approved by the
Regional Ethics Committee (REC-West 2013/1474). The study’s
clinical trial number is NCT02267057. The COSMOS trial was
also approved by the Regional Committee for Medical and Health
TABLE 1 | Descriptive statistics: age, gender, CSDD, MOBID-2, and MMSE
scores for the full sample.
Descriptives No. of observations
Age (mean, SD) 86.2 (7.5) 140
Female (%) 76.3 141
CSDD (mean, SD) 9.5 (4.7) 134
MOBID-2 (mean, SD) 2.6 (2.3) 120
MMSE (mean, SD) 8.8 (5.8) 141
Descriptive statistics for the full sample (n = 141). Number of observations refers
to how many patients have valid data for the different parameters. Abbreviations:
CSDD = Cornell Scale for Depression in Dementia, MOBID-2 = Mobilization-
Observation-Behavior-Intensity-Dementia-2 Pain Scale, MMSE = Mini-Mental
State Examination).
Research Ethics, West Norway (REK 2013/1765) and registered at
www.clinicaltrials.gov (NCT02238652).
Measurements
In both studies, sleep was measured with Actiwatch Spectrum
(Philips Respironics) for seven consecutive days.
NH patients may be quite inactive and in order to enhance
the possibility that movement would be detected we placed the
actigraphs on the patients’ dominant wrist. Prior studies have
found no discrepancy between data gathered from actigraphs
placed on different locations (Sadeh et al., 1994; Jean-Louis et al.,
1997). To enable better scoring of the actual time patients spent in
bed, NH staff was instructed to register bedtimes and rise times by
pushing the event button on the actigraph (light off at night and
light on in the morning). Instructions were given both verbally
and on a written instruction that was placed above the nightstand
in the patients’ rooms and in the call room.
The Actiware 6 (Respironics) scoring program and validated
algorithm was used for sleep/wake scoring. An actigraph consists
of an accelerometer and memory storage (Sivertsen et al., 2006).
Based on differences in movements associated with wakefulness
and sleep, an estimate of sleep-wake schedules is provided
(Sivertsen et al., 2006). We used medium sensitivity since this is
most commonly used., and sleep/waking status was determined
for each one-minute epoch. A skilled technician scored all activity
protocols. A standardized hierarchical approach was applied to
set rest intervals for the actigraphy data, using a) event markers
when possible; or b) light and activity data; or c) light or
activity data. If there was clear differentiation between active and
rest periods, alternatives b) and c) were implemented. If there
was no such clear differentiation, the actigraphy protocol was
excluded. In the main part of the DEP.PAIN.DEM study, 162
patients were enrolled (Erdal et al., 2018). However, 7 patients
had Parkinson’s disease, 11 did not consent to wear an actigraph,
8 patients removed the actigraph and 30 were excluded for
other reasons (missing data, malfunctioning actigraphs, etc.)
and were thus excluded in the actigraph sub-project. As a
result, 106 were included in the actigraph subproject in the
DEP.PAIN.DEM -study. 95 of these patients had valid MMSE
measurements and were thus included in the present study. In the
COSMOS study the actigraphy subproject included 107 patients,
24 of whom were excluded due to actigraph malfunction or
because of missing data. Of these 46 had dementia according to
the MMSE measurements and were thus included in the final
sample. The following parameters were derived from actigraphy
measurements: total sleep time (TST, min), time in bed (TiB,
hrs:min), sleep efficiency (SE,% [TST/TiB]∗100), sleep onset
latency (SOL, min), wake after sleep onset (WASO, min), early
morning awakening (EMA, min) and day time total sleep time
(DTS, min). DTS is a measure of sleep during daytime (from light
on in the morning to lights off at night) and TST is a measure of
sleep during nighttime (from light off in the night to lights on
in the morning).
We used the validated CSDD to measure depression (Barca
et al., 2010). The CSDD consists of 19 items assessing five
domains of depression (mood, behavioral disturbances, physical
signs, cyclic functions and ideational disturbances). A cut-off
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point of 8/9 has demonstrated the best accuracy for diagnosing
depression, ≥11 corresponds with severe depression according
to the ICD-10 criteria (Barca et al., 2010). We used the
following cut-offs in classifying the categorical variables: no
depression = CSDD ≤ 6, moderate depression = 7 ≤ CSDD ≤ 10,
severe depression = CSDD ≥ 11 (Barca et al., 2010).
Cognitive function was assessed using the validated MMSE
(Perneczky et al., 2006). The MMSE is a cognitive screening test
with a 30-point scale consisting of 20 tasks, which was developed
to differentiate potential dementia from normal functioning.
In the present study, we used the following cut-offs: a score
from 0 to 10 represents severe dementia, a score from 11 to 20
represents moderate dementia, a score from 21 to 25 represents
mild cognitive impairment, and a score from 26 to 30 represents
no dementia (Perneczky et al., 2006).
To measure pain, we used the Mobilization-Observation-
Behavior-Intensity-Dementia-2 Pain Scale (MOBID-2), a
validated staff-administered instrument (Husebo et al., 2010).
The instrument provides a total score based on observations
ranging from 0 to 10, in which 10 represents the worst possible
pain. In line with previous research, a cut-off of ≥3 was used to
indicate clinically relevant pain (Husebo et al., 2007, 2014).
Use of the following medications was registered based on
daily prescriptions registered in the patient health records:
N02A (opioids), N02B (other analgesics), N05C (hypnotics and
sedatives) and N06A (antidepressants). Patients were registered
categorically as users or non-users within each ATC group.
Statistical Analyses
Descriptive statistics (means, standard deviations and
percentages) were calculated for the full sample (Table 1) and for
the DEP.PAIN.DEM dataset and the COSMOS dataset separately
(Table 2). In addition, we conducted independent samples t-tests
to investigate if there were any statistically significant differences
in relevant characteristics between the respondents in the two
studies. Sleep characteristics were calculated for the full sample,
for patients with and without pain as measured with MOBID-2,
for patients with different degrees of depression according to the
CSDD, and with different degrees of cognitive function according
to the MMSE. We also conducted independent samples t-tests
to investigate if there were any statistically differences between
any of the different sleep parameters regarding these categories
(pain/no pain, moderate dementia/severe dementia and no
depression/moderate depression versus severe depression,
Table 3).
Two-step hierarchical multiple regression were conducted
to investigate how the different sleep parameters (total sleep
time, sleep efficiency, sleep onset latency, wake after sleep onset,
early morning awakening, time in bed and daytime total sleep
time) correlated with varying levels of pain, depression and
dementia in NH patients (see Table 4). Multicollinearity tests
using variance inflation factor showed no severe correlation
between independent variables that warrant corrective measures
These variables were entered in the first step of the hierarchical
regressions. In the second step, we adjusted for the use
of analgesics, antidepressants, sedative-hypnotics and opioids.
These variables were implemented in the regression models to
TABLE 2 | Descriptive statistics for age and CSDD, MOBID-2, and MMSE scores,
comparing data from the DEP.PAIN.DEM and COSMOS studies.
DEP.PAIN.DEM (n = 95) COSMOS (n = 46) P
Age (mean,SD) 85.6 (7.5) 87.6 (7.6) 0.13
CSDD (mean, SD) 11.1 (3.4) 5.5 (5.4) 0.00
MOBID-2 (mean, SD) 2.8 (2.2) 2.3 (2.4) 0.25
MMSE (mean, SD) 7.6 (6.0) 11.2 (4.5) 0.00
Descriptive statistics for the DEP.PAIN.DEM dataset and the COSMOS dataset.
Independent samples t-test show statistically significant differences between the
CSDD and MMSE scores.
investigate their potential effect on the associations between the
main variables of interest. We used categorical variables with the
cut-off points described above for pain, depression and dementia.
In addition, we include age and gender in both steps. We regarded
p < 0.05 as statistically significant in all analyses.
RESULTS
Mean age in the total sample was 86.2 years and 76.3%
were female (see Table 1 for the number of observations for
the different variables). The mean CSDD, MOBID-2, and
MMSE scores were 9.5 (SD 4.7), 2.6 (SD 2.3), and 8.8 (SD
5.8), respectively. The patients from the DEP.PAIN.DEM
trial had significantly higher depression and lower MMSE
mean scores than the patients in the COSMOS trial
(Table 2). In the total sample, 46.8% of the patients were
prescribed non-opioid analgesics, 27.7% were prescribed
sedative-hypnotics, 47.5% were prescribed antidepressants
and 17.7% were prescribed opioids (see Table 5). Table 4
reports sleep characteristics for the full sample (Panel A), for
those with and without pain (Panel B), for different levels
of depression (Panel C), and for various levels of cognitive
impairment (Panel D).
We comment on significant associations between the
predictors and the dependent variables for all models that are
reported in Table 4, but note that some of the regression models
are not statistically significant. The hierarchical regression
predicting TST showed that being in pain was associated
with more TST, while more severe depression was associated
with less TST (Table 4, Panel A). The regression predicting
SE showed that being in pain was associated with higher
SE (Table 4, Panel B). There were no significant results
in the regression predicting SOL (Table 4, Panel C). The
linear regression predicting WASO (Table 4, Panel D) showed
that more severe dementia and pain were both associated
with more WASO. The regression predicting EMA showed
no significant results (Table 4, Panel E). The regression
predicting DTS showed that being in pain was associated
with more DTS and that higher depression scores were
associated with less DTS. The final regression predicting TiB
showed that more severe dementia was associated with more
TiB. More severe depression was associated with less TiB
(Table 4, Panel G).
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TABLE 3 | Panel A: Sleep outcomes for the full sample, n = 141 (mean, SD)
TST (min) 516.3 (127.8)
SE (%) 70.2 (14.9)
SOL (min) 39.4 (51.6)
WASO (min) 138.8 (71.6)
EMA (min) 39.3 (44.3)
DTS (min) 210.3 (116.3)
TiB (hrs:min) 12:14 (1:14)
The following abbreviations are used: TST = total sleep time, SE = sleep efficiency, SOL = sleep onset latency, WASO = wake after sleep onset, EMA = early morning
awakening, DTS = daytime total sleep time, TiB = time in bed. The same abbreviations apply for all panels below.
TABLE 3 | Panel B: Sleep outcomes for patients with/without pain, n = 121 (mean, SD)
No pain (n = 61) Pain (n = 60) p
TST (min) 489.0 (101.0) 542.9 (148.0) 0.046
SE (%) 67.6 (13.1) 73.2 (16.8) 0.025
SOL (min) 37.5 (41.6) 37.7 (61.5) 0.435
WASO (min) 156.1 (76.1) 123.3 (65.0) 0.020
EMA (min) 43.5 (40.2) 33.5 (42.0) 0.190
DTS (min) 181.3 (98.4) 239.8 (131.6) 0.003
TiB (hrs:min) 12:07 (1:16) 12:17 (1:10) 0.916
TABLE 3 | Panel C: Sleep outcomes for patients with degrees of depression, n = 133 (mean, SD)
No depression (n = 26) Moderate depression (n = 55) Severe depression (n = 52) p
TST (min) 548.5 (113.5) 521.9 (142.8) 497.7 (119.0) 0.985
SE (%) 72.9 (14.6) 71.5 (16.7) 67.9 (13.0) 0.830
SOL (min) 35.7 (47.5) 39.1 (62.1) 43.2 (44.2) 0.555
WASO (min) 138.3 (90.7) 127.5 (63.8) 150.1 (70.1) 0.281
EMA (min) 33.4 (32.3) 37.9 (48.2) 39.9 (42.8) 0.446
DTS (min) 265.5 (118.0) 211.0 (116.0) 193.4 (109.7) 0.343
TiB (hrs:min) 12:35 (1:05) 12:07 (1:08) 12:11 (1:25) 0.417
No depression = CSDD < 6, moderate depression = 7 < CSDD < 10, severe depression = CSDD ≥ 11.
TABLE 3 | Panel D: Sleep outcomes for patients with different levels of dementia, n = 141 (mean, SD).
Moderate dementia (n = 64) Severe dementia (n = 77) p
TST (min) 516.0 (113.6) 516.6 (139.2) 0.980
SE (%) 73.0 (11.9) 67.9 (16.8) 0.039
SOL (min) 32.0 (33.7) 45.6 (62.3) 0.101
WASO (min) 121.9 (50.3) 152.8 (83.1) 0.007
EMA (min) 34.5 (35.8) 43.4 (50.1) 0.224
DTS (min) 200.8 (114.5) 218.3 (117.9) 0.376
TiB (hrs:min) 11:45 (1:14) 12:38 (1:05) 0.000
No dementia = MMSE ≥ 26, Mild dementia = MMSE score from 21 ≤ MMSE ≤ 25 to ≥ 25, Moderate dementia = MMSE score from 11 ≤ MMSE ≤ 20, Severe
dementia = MMSE score MMSE ≤ 10.
In the second step of the hierarchical regressions, we
adjusted for the use of analgesics, antidepressants, sedative-
hypnotics and opioids. In all the regressions, the results
reported above held when adjusting for the use of these
medications. In addition, we noted that in the regression
predicting DTS, the negative association between the use of
sedatives and DTS was only marginally insignificant (p = 0.051)
(Table 4, Panel F). Furthermore, in the regression predicting
TiB, the use of sedatives was associated with less TiB
(Table 4, Panel G).
In order to correct for multiple comparisons, we conducted
False Discovery Rate corrections. Overall, the results largely held
when taking these corrections into account. The exception was
that the significant association between depression and TST
became insignificant (p = 0.034 with a corrected threshold of
p = 0.021).
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DISCUSSION
Contrary to our hypotheses, NH patients with more severe
pain and dementia had longer total sleep time and slept
more during daytime, which indicates that NH patients
with dementia and pain sleep more. Furthermore, their
sleep efficiency was higher, indicating that the patients had
more sleep within the time they spent in bed. In line
with our hypotheses, our results showed that more severe
dementia was associated with more time spent awake at night.
Furthermore, people with more severe dementia spent more
time in bed and people with more severe depression slept
less at daytime and had less total sleep time. In addition,
when adjusting for the use of medications, we found that
TABLE 4 | hierarchical regression models for various sleep parameters, with and without adjusting for medication use.
Panel A: Hierarchical regression models predicting total sleep time (TST) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F p
1 0.095 0.095 2.24 0.056
Pain 63.017 24.286 0.243 0.011
Depression −36.388 16.941 −0.209 0.034
Dementia 8.307 25.043 0.032 0.741
Age 0.347 1.622 0.021 0.831
Gender 22.425 29.268 0.074 0.445
2 0.147 0.052 1.96 0.052
Pain 60.038 24.207 0.232 0.015
Depression −34.612 17.183 −0.198 0.047
Dementia 3.150 25,756 0.012 0.903
Age 0.649 1.613 0.039 0.688
Gender 14.843 29.346 0.049 0.614
Analgesics −0.435 24.880 −0.002 0.986
Sedatives −55.265 29.105 −0.187 0.060
Antidepressants 22.888 24.473 0.088 0.352
Opioids 53.581 32.651 0.158 0.104
The table reports hierarchical regression models. Step 1 reports the correlates pain, depression, dementia, age, and gender. Step 2 also adjusts for analgesics, sedatives,
antidepressants, and opioids. For unstandardized coefficients, B and SE signifies beta values and standard errors. For standardized coefficients, β and p signifies beta
values and p values, respectively. F signifies the F value from statistical tests and p value associated with the test. The same information applies to all other panels below.
Bold values indicate p-values < 0.05.
TABLE 4 | Panel B: Hierarchical regression models predicting sleep efficiency (SE) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE B p R2 R2 change F p
1 0.098 0.098 2.296 0.050
Pain 6.706 2.821 0.223 0.019
Depression −2.388 1.968 −0.118 0.228
Dementia −5.299 2.909 −0.174 0.071
Age −0.011 0.188 −0.006 0.954
Gender 3.503 3.400 0.099 0.305
2 0.117 0.020 1.507 0.155
Pain 6.438 2.865 0.214 0.027
Depression −2.262 2.034 −0.111 0.268
Dementia −5.484 3.048 −0.181 0.075
Age 0.005 0.191 0.003 0.977
Gender 2.933 3.473 0.083 0.400
Analgesics 0.793 2.944 0.026 0.788
Sedatives −3.150 3.444 −0.092 0.363
Antidepressants 1.189 2.896 0.039 0.682
Opioids 4.852 3.864 0.123 0.212
Bold values indicate p-values < 0.05.
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TABLE 4 | Panel C: Hierarchical regression models predicting sleep onset latency (SOL) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F P
1 0.024 0.024 0.520 0.760
Pain −2.236 10.225 −0.022 0.820
Depression −1.881 7.132 −0.027 0.793
Dementia 15.290 10.543 0.145 0.150
Age −0.209 0.683 −0.031 0.761
Gender −6.753 12.322 −0.055 0.585
2 0.046 0.022 0.552 0.833
Pain −1.950 10.375 −0.019 0.851
Depression −1.369 7.365 −0.019 0.853
Dementia 18.519 11.039 0.175 0.096
Age −0.284 0.691 −0.042 0.682
Gender −4.465 12.578 −0.036 0.723
Analgesics −8.861 10.664 −0.084 0.408
Sedatives 13.652 12.474 0.114 0.276
Antidepressants −7.538 10.489 −0.072 0.474
Opioids −6.741 13.994 −0.049 0.631
TABLE 4 | Panel D: Hierarchical regression models predicting wake after sleep onset (WASO) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F p
1 0.127 0.127 3.093 0.012
Pain −37.192 13.432 −0.255 0.007
Depression 6.513 9.370 0.066 0.488
Dementia 36.154 13.851 0.246 0.010
Age 0.854 0.897 0.091 0.343
Gender −8.130 16.188 −0.048 0.617
2 0.152 0.025 2.038 0.042
Pain −36.010 13.590 −0.247 0.009
Depression 5.077 9.647 0.052 0.600
Dementia 31.717 14.459 0.216 0.031
Age 0.907 0.905 0.096 0.319
Gender −7.616 16.475 −0.045 0.645
Analgesics −0.880 13.968 −0.006 0.950
Sedatives −6.878 16.339 −0.041 0.675
Antidepressants 8.648 13.739 0.059 0.530
Opioids −24.746 18.330 −0.130 0.180
Bold values indicate p-values < 0.05.
patients who were prescribed sedative-hypnotic medications
spent less time in bed.
To the best of our knowledge, this study is the first to explore
how different levels of pain and depression correlate with a
wide set of actigraphy-measured sleep parameters in NH patients
with dementia (see Table 4). The results are of key importance
since they provide new and valuable insight on the relationship
between NH patients’ sleep, including sleep during daytime,
and its associations with different levels of pain and depression.
In light of previous research that has demonstrated that pain
conditions are commonly associated with worse sleep in people
without dementia (e.g., Andersen et al., 2018), the results from
the present study are particularly interesting.
The results from the present study were unexpected.
A potential explanation for these results could be that patients in
pain receive more analgesics, antidepressants, sedative-hypnotics
or opioids and thereby experience more sedation as an intended
or adverse treatment effect. In turn, sedation and lack of
movement could be recorded as sleep using actigraphy. However,
we controlled for the use of different medications, rendering this
explanation unlikely.
Another potential explanation of these somewhat surprising
results may be that many older adults who experience chronic
pain may develop behavior in which painful movements
are avoided. This is known as the pain-avoidance effect
(Vlaeyen and Linton, 2012; Achterberg et al., 2013). If this
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TABLE 4 | Panel E: Hierarchical regression models predicting early morning awakening (EMA) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F P
1 0.069 0.069 1.560 0.178
Pain −11.767 7.387 −0.152 0.114
Depression 4.197 5.153 0.080 0.417
Dementia 8.122 7.618 0.104 0.289
Age −0.189 0.493 −0.038 0.703
Gender −14.590 8.903 −0.161 0.104
2 0.075 0.007 0.923 0.508
Pain −11.959 7.556 −0.154 0.117
Depression 3.926 5.364 0.075 0.466
Dementia 9.337 8.040 0.119 0.248
Age 0.228 0.503 −0.045 0.652
Gender −13.902 9.160 −0.153 0.132
Analgesics 0.981 7.766 0.013 0.900
Sedatives 6.976 9.085 0.079 0.444
Antidepressants −0.1022 7.639 −0.013 0.894
Opioids 0.289 10.192 0.003 0.977
TABLE 4 | Panel F: Hierarchical regression models predicting daytime total sleep time (DTS) with and without adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F P
1 0.169 0.169 4.261 0.001
Pain 69.229 21.608 0.289 0.002
Depression −49.988 15.272 −0.308 0.001
Dementia 31.684 22.409 0.131 0.160
Age −0.311 1.455 −0.020 0.831
Gender −31.897 26.025 −0.114 0.223
2 0.205 0.036 2.891 0.004
Pain 71.687 21.766 0.299 0.001
Depression −44.710 15.652 −0.275 0.005
Dementia 25.192 23.223 0.105 0.281
Age −0.052 1.457 −0.003 0.972
Gender −39.097 26.257 −0.140 0.140
Analgesics −0.492 22.312 −0.002 0.982
Sedatives −51.510 26.053 −0.189 0.051
Antidepressants −19.086 22.008 −0.080 0.390
Opioids 12.829 29.960 0.040 0.428
Bold values indicate p-values < 0.05.
interpretation is valid, it would imply that the patients may in
fact not be sleeping but are lying still in order to avoid pain, and
by extension this highlight that pain assessment is fundamental.
When a patient is lying still, it may be interpreted as sleep when
measured with actigraphy. The fact that DTS was also higher in
NH patients with pain and dementia may indicate that painful
movements/activity were avoided at daytime as well. At the same
time, it is noteworthy that previous research shows more agitated
behavior among patients with mild to moderate pain (Husebo
et al., 2014). In Blytt et al. (2018a), which is based on sleep-
related data from the DEP.PAIN.DEM trial, we found that in
the full sample, pain treatment improved sleep as measured
with actigraphy compared to placebo after one week with pain
treatment (paracetamol and buprenorphine). The results from
the DEP.PAIN.DEM trial do not allow differentiation between
sedation as a side-effect of the administered treatment and
actual sleep. Importantly, we found no long-term effect of pain
treatment on sleep (Blytt et al., 2018b). In the present study,
we registered the use of different medications that can lead to
sedation as a side-effect. However, this did not affect the results,
and the only finding related to medication use was that the use of
sedatives was associated with less time spent in bed.
Based on the present findings, we argue that there is a
need for studies examining more thoroughly and systematically
the association between pain, depression and sleep. It is
furthermore important to acknowledge that it is very difficult to
Frontiers in Psychology | www.frontiersin.org 8 April 2021 | Volume 12 | Article 633959
fpsyg-12-633959 April 19, 2021 Time: 12:58 # 9
Blytt et al. Sleep, Pain and Depression
TABLE 4 | Panel G: Hierarchical regression models with and without predicting time in bed (TiB) adjusting for medication use.
Unstandardized coefficients Standardized coefficients
Step Predictor B SE β p R2 R2 change F P
1 0.228 0.228 6.261 0.00
Pain 618.941 765.203 0.070 0.420
Depression −1651.064 533.769 −0.277 0.003
Dementia 3978.952 789.043 0.447 0.000
Age 0.48.800 51.095 0.086 0.955
Gender −613.861 922.179 −0.059 0.507
2 0.313 0.085 5.169 0.00
Pain 511.950 740.930 0.058 0.491
Depression −1611.413 525.942 −0.271 0.003
Dementia 3698.456 788.338 0.415 0.000
Age 62.678 49.355 0.110 0.207
Gender −869.196 898.208 −0.084 0.335
Analgesics −449.644 761.529 −0.050 0.556
Sedatives −2416.144 890.838 −0.240 0.008
Antidepressants 1315.321 749.052 0.149 0.082
Opioids 1555.759 999.381 0.135 0.123
Bold values indicate p-values < 0.05.
ascertain pain in people with dementia. The use of observation-
based pain instruments applied by a proxy-rater who is
familiar with the patients is a common method to assess
pain in this population. Since a patient’s behavior is typically
changed in reaction to experiencing pain, it is essential to
examine pain expressions in relation to the person’s usual
behavior (Hadjistavropoulos et al., 2014). Most tools used for
classifying pain in NH patients are developed against this
backdrop (Corbett et al., 2012; Flo et al., 2014; Lichtner
et al., 2014). The MOBID-2 instrument has good validity,
interrater and test-retest reliability, and responsiveness to
change has been shown (Husebo et al., 2014). Yet, pain
is a complex phenomenon, and we cannot be sure that
the patient is experiencing pain, and in what intensity,
location and duration.
Previous research indicates that increased wakefulness and
fragmented sleep at night are common sleep problems in
patients with dementia (McCleery et al., 2016). Our results
showed that the patients with more severe dementia spent more
time awake during the night. Sleep problems in patients with
dementia may be a result of neural loss in the suprachiasmatic
nuclei and/or other neuropathological changes to sleep-wake
circuits (Swaab et al., 1985; Van Someren, 2000). The results
of the present study indicate that as dementia progresses, sleep
problems may be exacerbated. While more severe dementia
was also associated with spending more time in bed, we
cannot tell whether this is a result of the patient’s own
wishes, or NH routines.
Previous studies investigating sleep and depression have found
that 60 to 80% of depressed adults and older adults report
having difficulty falling or staying asleep or being tired the next
day (Almeida and Pfaff, 2005; Ancoli-Israel, 2009). Furthermore,
depression in people with dementia is associated with lack of
initiative and reduced memory, and there is thus overlap between
TABLE 5 | Descriptive statistics for the use of analgesics, sedatives,
antidepressants and opioids.









the core symptoms of dementia and depression (Brailean et al.,
2016). The present study indicates that the patients with more
severe depression was somewhat more active as we found that
they slept less during daytime, had lower total sleep time and
spent less time in bed. A potential explanation for this could be
agitation – a symptom often seen in people with dementia and
depression (Husebo et al., 2014).
As pointed out by McCleery et al. (2016), there is a lack
of evidence regarding drug treatment of sleep problems in
people with dementia, and this is thus highly needed. However,
the present study was not designed to look at the effect of
sedatives on sleep in this population. Therefore, we cannot
be sure if the patients receiving sedatives (27.7% of the total
sample) were systematically different in other ways that can
explain these results.
Limitations
This study has several limitations. Due to the cross-sectional
design of the study, we cannot draw any causal conclusions.
Furthermore, the COSMOS and the DEP.PAIN.DEM trials have
somewhat different inclusion and exclusion criteria. Importantly,
Frontiers in Psychology | www.frontiersin.org 9 April 2021 | Volume 12 | Article 633959
fpsyg-12-633959 April 19, 2021 Time: 12:58 # 10
Blytt et al. Sleep, Pain and Depression
the DEP.PAIN.DEM study, from which most of the data is
derived, had depression and dementia as inclusion criteria
(CSDD ≥ 8, MMSE ≤ 20). As the results from the
independent samples t-tests showed, the patients from the
DEP.PAIN.DEM trial had significantly higher depression scores
and lower MMSE scores. This implies that the patients from
the two trials may not be comparable, which may affect
generalizability. The results from the present study may arguably
be generalized to NH patients with dementia and probable
symptoms of depression.
To measure sleep in the NH setting is challenging due to
patients’ reduced ability to give valid self-report (Blytt et al.,
2017). Therefore, objective measurement using actigraphy or
use of proxy-rater assessment tools (where health personnel
or relatives answer on behalf of the patient) are the current
alternatives. Both have several limitations. When using
actigraphy, immobility is recorded as sleep, which makes it
difficult to interpret the results. Furthermore, previous research
has shown that SOL has been particularly difficult to ascertain
(Marino et al., 2013). When proxy-rater assessment tools are
evaluated, they are often compared with actigraphy as the
gold standard (Blytt et al., 2017; Hjetland et al., 2020). This
indicates that actigraphy is considered a better method for
measuring sleep in this population. When sleep is evaluated
using proxy-rater assessment tools like the Neuropsychiatric
Inventory and the Cornell Scale for Depression in Dementia,
raters report significantly fewer sleep problems compared to
actigraphy (Blytt et al., 2017). This highlights that measuring
sleep in this population is difficult. However, individual sleep
diaries – addressed by the patient’s primary nurse – would have
strengthened the study.
It is furthermore important to note that we have just
conducted a coarse mapping of the medications; N02A (opioids),
N02B (other analgesics), N05C (hypnotics and sedatives), and
N06A (antidepressants). However, effects such as sedation may
differ within the different drug groups and according to the
prescribed dose. Additionally, we did not assess whether the daily
prescriptions were in fact administered to the patient. Only daily
prescribed treatments were recorded we did not control for the
use of as-needed treatment.
Another limitation in the present study was that we did
not have complete datasets for all the different variables (for
an overview of missing data, see the number of observations
in Table 1). We cannot be sure whether the results would
be different if we had complete data for all the relevant
parameters investigated.
Together, the results of the present study revealed new
and interesting insights on the relationship between sleep,
pain and depression in a fragile patient group. Importantly,
the results indicated that being in pain was associated
with more sleep as measured with actigraphy, also when
controlling for use of potentially sleep-enhancing medications
like sedative-hypnotics, analgesics, opioids and antidepressants.
Future research should focus on further investigating the
mechanisms underlying these results.
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